Efficacy News and Research

RSS

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

International researchers to assess role of pre-clinical animal models in drug discovery

The New York Academy of Sciences and the Global Medical Excellence Cluster (GMEC), in collaboration with Imperial College London and King's College London, will host a two-day scientific conference, "Animal Models and Their Value in Predicting Drug Efficacy and Toxicity," that will provide a forum to critically examine the role of pre-clinical animal models in drug discovery.

7 Sep 2011

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

Neurosurgery researchers at UC Davis Health System have used a new, leading-edge stem cell therapy to promote the growth of bone tissue following the removal of cervical discs -- the cushions between the bones in the neck -- to relieve chronic, debilitating pain.

7 Sep 2011

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Computer-tailored nutrition education not effective in reducing fat intake

As lifestyles get busier and waistlines get bigger; many people are turning to online nutrition programs. In promotion of healthful nutrition behaviors, computer-tailored nutrition education has been identified as a promising health education strategy, especially in the promotion of lower fat intake.

7 Sep 2011

IOF presents eight young investigator awards to researchers across the world

Eight IOF Young Investigator Awards were presented by the International Osteoporosis Foundation (IOF) to young researchers from Australia, China, India and Japan, in recognition of their outstanding work. The awards, valued at 1,000 USD each, were awarded to the highest scored abstracts by researchers under the age of 40.

7 Sep 2011

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Discovery Labs, Inc. today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN(lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

6 Sep 2011

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke.

6 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that a group of certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

Efficacy News and Research

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

International researchers to assess role of pre-clinical animal models in drug discovery

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Computer-tailored nutrition education not effective in reducing fat intake

IOF presents eight young investigator awards to researchers across the world

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Latest News